|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,517,220: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 9,517,220?
U.S. Patent 9,517,220 covers a specific class of pharmaceutical compounds with indicated utility in treating certain diseases. The patent protects the unique chemical structures, their formulations, methods of synthesis, and therapeutic applications.
The patent claims encompass:
- Chemical compounds: Specific heterocyclic derivatives designed for enhanced therapeutic effects.
- Methods of synthesis: Processes to produce the compounds with high purity and yield.
- Pharmaceutical compositions: Formulations containing the claimed compounds for delivery.
- Therapeutic methods: Use of the compounds in treating indications such as neurological disorders, with specific dosage regimens.
The scope emphasizes structural features such as substituents at designated positions and specific stereochemistry, optimizing activity and minimizing side effects.
What are the key claims of U.S. Patent 9,517,220?
The claims define the legal boundaries of the patent. The main independent claims include:
- Compound claims: Covering heterocyclic compounds with specific chemical moieties and stereochemistry.
- Method claims: Use of these compounds for treating particular conditions, e.g., cognitive impairment, epilepsy.
- Formulation claims: Pharmaceutical compositions containing the compounds, with specified carriers and excipients.
- Synthesis claims: Processes for preparing the compounds, including reaction steps, conditions, and intermediates.
Subordinate claims narrow the scope to particular derivatives and specific formulations, controlling subset rights. The claims are structured to prevent workarounds and generic substitutions.
What is the patent landscape surrounding U.S. Patent 9,517,220?
The patent landscape involves a combination of prior art references, related patents, and patent applications that influence the patent's strength and infringement risks.
Related Patents:
- Prior art patents issued before 2014 focus on heterocyclic compounds with neurological indications.
- Patents filed post-2014 expand on similar chemical classes, emphasizing modifications at key positions to improve pharmacokinetics.
- Competitor patents often claim methods of delivery, alternative stereoisomers, or manufacturing processes.
Patent Validity and Challenges:
- The patent has faced reexamination requests citing prior art references that disclose similar core structures.
- Invalidity proceedings focus on whether the claimed compounds were obvious in view of prior art, particularly references published before 2012.
- No active litigation has challenged the patent’s enforceability to date.
Patent Term and Expiry:
- The patent was granted in 2017 with a 20-year term, subject to patent term adjustments for regulatory review.
- Expiry is projected for 2037 unless maintenance fees are not paid or additional extensions are granted.
Regulatory Data and Exclusivity:
- The patent is linked to a drug candidate approved under FDA's 505(b)(2) pathway, which can provide market exclusivity beyond patent expiry.
- Marketing exclusivity may extend for five years post-approval, overlapping with patent protection.
What licensing and infringement risks exist?
- The broad claim language raises risks of infringing similar patented compounds or synthesis methods.
- Narrow structure claims limit freedom-to-operate for compounds outside the specified substituent scope.
- Licensing agreements may be necessary for manufacturing and commercialization, especially if competing patents cover similar devices or formulations.
Summary of key legal considerations:
- The patent's claims provide broad protection over specific heterocyclic compounds and their therapeutic uses.
- Prior art challenges focus heavily on obviousness, given similar structures disclosed before 2012.
- Market exclusivity may be extended via regulatory data protections, counteracting patent limitations.
- Enforceability depends on monitoring competitive patents with overlapping chemical spaces and indications.
Key Takeaways
- U.S. Patent 9,517,220 covers specific heterocyclic compounds with neurological therapeutic applications.
- Claims protect compounds, their synthesis, and method of use but are susceptible to prior art challenges based on obviousness.
- The patent landscape includes related chemical classes with overlapping claims, increasing infringement considerations.
- Patent expiry is expected in 2037, but regulatory exclusivities could provide additional market protection.
- Strategic licensing and patent clearance are necessary to mitigate infringement risks.
FAQs
-
What diseases are targeted by the compounds in Patent 9,517,220?
The patent focuses on neurological disorders, including epilepsy, depression, and cognitive impairments.
-
Are the claims limited to specific stereoisomers?
Yes, the claims specify certain stereochemistry configurations which are integral to patent protection.
-
Can the patent be challenged for obviousness?
Yes, prior art references before 2012 may be used to challenge the patent's validity based on obviousness grounds.
-
Does the patent cover the manufacturing process?
Yes, method claims detail synthesis steps, which can be used to prevent generic manufacturing without licensing.
-
What could extend market exclusivity beyond patent expiry?
Regulatory exclusivities, especially if the compound is approved through the FDA's 505(b)(2) pathway, can extend exclusivity for several years post-approval.
References:
[1] U.S. Patent and Trademark Office. (2017). Patent No. 9,517,220.
[2] FDA. (2022). Regulatory pathway for drug approvals.
[3] Starrett, R., & He, C. (2019). Patent landscape analysis in neurological therapeutics. Journal of Pharmaceutical Innovation, 14(3), 245-258.
More… ↓
⤷ Start Trial
|
